Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2003-06-30
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Whether the cholesterol lowering effects of plant sterols and stanols also favorably affect endothelial function in humans is currently unknown. Apart from their cholesterol lowering effects, plant sterols and stanols might have other effects like effects on red blood cell properties, cognitive performance and antioxidant status. Especially to evaluate effects on this type of parameters long-term daily consumption of plant sterols and stanols is necessary. These questions will be answered in statin treated patients since functional foods enriched with plant sterol and stanol esters have been recommended for statin-users as an "add on" therapy. This may ultimately lead to a lower dose of statins or an increased number of patients that reach the target for LDL-cholesterol reduction.
AIM The major objective of the present proposal is to examine the effects of a long-term consumption of plant sterols and stanols on the endothelial function of the vessel wall in statin-treated patients.
STUDY DESIGN Subjects: The subjects will be recruited among men and women in Maastricht and surroundings, aged between 18 and 70 years. Participation will be on voluntary basis. People who are willing to participate will be invited for two screening visits.
Experimental design: The present study is a double-blind, randomized parallel intervention trial with 60 statin-treated subjects, in which the metabolic effects of a long term (90 weeks) consumption of plant sterols and stanols (2.5 g/day) will be studied. After a run-in period of 5 weeks the subjects will be randomly divided into three groups of 20 subjects each. One group will continue with the control margarine without added plant sterols and stanols, one group will use a plant sterol margarine and the last group will use a plant stanol margarine for 85 weeks. The major endpoint will be endothelial function of the vessel wall, and in addition various parameters related to lipids and lipoprotein metabolism, erythrocyte characteristics and cognitive performance will be measured.
Risk for subjects The margarines containing the plant sterols and stanols are safe and palatable. Venipunctures and other (non-invasive) measurements are carried out by skilled persons and not of any risk. A subject will spend approximately 1 hour a month in participating in the studies.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. placebo
placebo margarine
No intervention
placebo margarine
2. stanol ester
margarine with plant stanol ester
stanol ester
enriched margarine
3. sterol ester
margarine with plant sterol ester
sterol ester
enriched margarine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
stanol ester
enriched margarine
sterol ester
enriched margarine
No intervention
placebo margarine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable dietary habits
Exclusion Criteria
* Impairment of renal function, as evidenced by increased serum creatinine \> 150 mcmol/L
* Hepatic diseases as manifested by ALT, AST, GGT, total bilirubin or ALP \> 2 times the upper limit of normal
* Severe medical conditions that might interfere with the study such as epilepsy, asthma, and rheumatoid arthritis.
* Use of medication such as corticosteroids, diuretics or lipid lowering medication other than statins
* Unstable body weight (weight gain or loss \>3 kg in the past three months)
* Abnormal hematological profile
* Quetelet-index \> 32 kg/m2
* Diastolic blood pressure \> 100 mm Hg or systolic \> 160 mm Hg
* Abuse of drugs and/or alcohol
* Use of sterol or stanol ester products within the previous 30 days
* Participation in another study within 1 months prior to the screening visit
* Pregnant women or women with child-wish within the duration of the study
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ZonMw: The Netherlands Organisation for Health Research and Development
OTHER
Maastricht University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maastricht UMC
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jogchem Plat, PhD
Role: PRINCIPAL_INVESTIGATOR
Maastricht UMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maastricht University
Maastricht, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MEC03-046.3
Identifier Type: -
Identifier Source: org_study_id